EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine